EUCTR2008-005867-33-GB
Active, not recruiting
Phase 1
Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Primovist/Eovist in patients with moderate to severe renal impairment for the development of nephrogenic systemic fibrosis (NSF) based on diagnostically specific clinical and histopathologic information. - Primovist/Eovist in Renally Impaired patients (the PERI study)
ConditionsPatients with moderate (eGFR 30 – 59 mL/min/1.73 m2) to severe renal impairment (eGFR < 30 mL/min/1.73 m2) scheduled to undergo contrast-enhanced MRI with Primovist/Eovist.MedDRA version: 14.1Level: LLTClassification code 10038469Term: Renal impairment NOSSystem Organ Class: 10038359 - Renal and urinary disorders
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Patients with moderate (eGFR 30 – 59 mL/min/1.73 m2) to severe renal impairment (eGFR < 30 mL/min/1.73 m2) scheduled to undergo contrast-enhanced MRI with Primovist/Eovist.
- Sponsor
- Bayer HealthCare AG
- Enrollment
- 364
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient must be scheduled for CE\-MRI with Primovist/Eovist based on careful risk/benefit evaluation at the recommended dose in one of the approved indications
- •Patient must fulfill criteria for moderate (eGFR 30 – 59 mL/min/1\.73 m2\) to severe (eGFR \< 30 mL/min/1\.73 m2\) renal impairment.
- •Patient must sign study\-specific informed consent.
- •Patients are to be imaged according to the magnetic resonance (MR) imaging protocols in the participating institutions, which include that physicians are to comply with the general precaution measures of MR imaging.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 1000
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 1000
Exclusion Criteria
- •GBCA\-enhanced MRI (or administration of a GBCA for any other CE imaging procedure) other than Primovist/Eovist within 12 months prior to administration of Primovist/Eovist
- •\-Rationale for selected time window: to minimize level of confounding from prior administration of GBCA for the estimation of risk of NSF for Primovist/Eovist while at the same time avoiding the elimination of too many potential participants from the study.
- •\-Exposure to GBCA within 12 months prior to administration of Primovist/Eovist will be determined at the time of the initial evaluation via history (elicited from patient) and review of patient’s medical records, if available at that time. Subsequently, a more thorough analysis of the patient’s medical records will be carried out to ascertain the accuracy of the GBCA exposure information obtained at the time of the initial evaluation.
- •History of existing NSF
- •Age less than 18 years
- •Patients who are clinically unstable and whose clinical course is unpredictable
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to severe renal impairment for the development of nephrogenic systemic fibrosis (NSF) based on diagnostically specific clinical and histopathologic information - Safety of Gadovist® in Renally Impaired Patients (the GRIP study)Patients with moderate to severe renal impairment.MedDRA version: 9.1Level: LLTClassification code 10038474Term: Renal insufficiencyEUCTR2008-004496-22-FRBayer Health Care AG (study performed by Bayer Schering Pharma AG)926
Active, not recruiting
Not Applicable
Saftey of Primovist/Eovist in Renally Impaired patientsPatients with moderate (eGFR 30 – 59 mL/min/1.73 m2) to severe renal impairment (eGFR < 30 mL/min/1.73 m2) scheduled to undergo contrast-enhanced MRI with Primovist/Eovist.MedDRA version: 15.1Level: LLTClassification code 10038469Term: Renal impairment NOSSystem Organ Class: 100000004857Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2008-005867-33-DEBayer HealthCare AG1,000
Active, not recruiting
Not Applicable
Saftey of Primovist/Eovist in Renally Impaired patientsPatients with moderate (eGFR 30 – 59 mL/min/1.73 m2) to severe renal impairment (eGFR < 30 mL/min/1.73 m2) scheduled to undergo contrast-enhanced MRI with Primovist/Eovist.MedDRA version: 14.0Level: LLTClassification code 10038469Term: Renal impairment NOSSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2008-005867-33-ATBayer HealthCare AG1,000
Active, not recruiting
Phase 1
Prospective non-randomized (pharmacoepidemiologic) cohort study (open-label, multicenter) to assess the magnitude of potential risk with the administration of Gadovist® in patients with moderate to severe renal impairment for the development of nephrogenic systemic fibrosis (NSF) based on diagnostically specific clinical and histopathologic information - Safety of Gadovist® in Renally Impaired Patients (the GRIP study)Patients with moderate to severe renal impairment.MedDRA version: 9.1Level: LLTClassification code 10038474Term: Renal insufficiencyEUCTR2008-004496-22-ATBayer Health Care AG (study performed by Bayer Schering Pharma AG)1,000
Active, not recruiting
Not Applicable
Safety of Gadovist® in Renally Impaired PatientsPatients with moderate to severe renal impairment.MedDRA version: 14.1Level: LLTClassification code 10038469Term: Renal impairment NOSSystem Organ Class: 10038359 - Renal and urinary disordersTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2008-004496-22-DEBayer Health Care AG1,000